Biotech breakthrough: Mersana Therapeutics stock soars 23% after blowing past Q3 expectations

Pallavi Madhiraju- November 13, 2024 0

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment, saw its shares leap by 23% following a robust ... Read More

Merck and Mersana Therapeutics to co-develop new immunostimulatory ADCs

Raghuram Kadari- December 29, 2022 0

Merck has announced a collaboration with US-based Mersana Therapeutics to discover new antibody-drug conjugates (ADCs) by leveraging the latter’s proprietary Immunosynthen STING-agonist ADC platform. The ... Read More